Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
293
archived clinical trials in
Benign Prostate Hyperplasia

UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated:  12/31/1969
Jean Brown Research
706
mi
from 98109
Salt Lake City, UT
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated: 12/31/1969
Jean Brown Research
706
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated:  12/31/1969
Genesis Research
1065
mi
from 98109
San Diego, CA
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated: 12/31/1969
Genesis Research
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated:  12/31/1969
Advanced Urology Institute
2530
mi
from 98109
Daytona Beach, FL
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated: 12/31/1969
Advanced Urology Institute
2530
mi
from 98109
Daytona Beach, FL
Click here to add this to my saved trials
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated:  12/31/1969
Pinellas Urology Inc
2525
mi
from 98109
Saint Petersburg, FL
UroLift System TOlerability and ReCovery When Administering Local Anesthesia
L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia
Status: Enrolling
Updated: 12/31/1969
Pinellas Urology Inc
2525
mi
from 98109
Saint Petersburg, FL
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
Arizona Institute of Urology
1220
mi
from 98109
Tucson, AZ
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
Arizona Institute of Urology
1220
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
Urology Associates of Denver
1025
mi
from 98109
Denver, CO
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
Urology Associates of Denver
1025
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
South Florida Medical Research
2725
mi
from 98109
Aventura, FL
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
South Florida Medical Research
2725
mi
from 98109
Aventura, FL
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
Southern Illinois University
1704
mi
from 98109
Springfield, IL
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
Southern Illinois University
1704
mi
from 98109
Springfield, IL
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
Metro Urology
1407
mi
from 98109
Woodbury, MN
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
Metro Urology
1407
mi
from 98109
Woodbury, MN
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
Manhattan Medical Research
2402
mi
from 98109
New York, NY
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
Manhattan Medical Research
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
The Urology Group
1967
mi
from 98109
Cincinnati, OH
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
The Urology Group
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
2024
mi
from 98109
Cleveland, OH
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
2024
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
Carolina Urologic Research Center
2435
mi
from 98109
Myrtle Beach, SC
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
Carolina Urologic Research Center
2435
mi
from 98109
Myrtle Beach, SC
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
UT Southwestern
1682
mi
from 98109
Dallas, TX
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
UT Southwestern
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
Urology San Antonio
1780
mi
from 98109
San Antonio, TX
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
Urology San Antonio
1780
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
Jean Brown Research
706
mi
from 98109
Salt Lake City, UT
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
Jean Brown Research
706
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
Chesapeake Urology
2325
mi
from 98109
Towson, MD
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
Chesapeake Urology
2325
mi
from 98109
Towson, MD
Click here to add this to my saved trials
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated:  12/31/1969
Texas Urology
mi
from 98109
Carrollton, TX
Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)
Status: Enrolling
Updated: 12/31/1969
Texas Urology
mi
from 98109
Carrollton, TX
Click here to add this to my saved trials
Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams
Phase II, Single Arm Prospective Study to Evaluate Safety and Efficacy of Prostate Artery Embolization in Patients With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams
Status: Enrolling
Updated:  12/31/1969
Tampa General Hospital
2527
mi
from 98109
Tampa, FL
Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams
Phase II, Single Arm Prospective Study to Evaluate Safety and Efficacy of Prostate Artery Embolization in Patients With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams
Status: Enrolling
Updated: 12/31/1969
Tampa General Hospital
2527
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2118
mi
from 98109
Anniston, AL
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2118
mi
from 98109
Anniston, AL
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2038
mi
from 98109
Huntsville, AL
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2038
mi
from 98109
Huntsville, AL
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1431
mi
from 98109
Anchorage, AK
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1431
mi
from 98109
Anchorage, AK
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
998
mi
from 98109
Laguna Hills, CA
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
998
mi
from 98109
Laguna Hills, CA
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1008
mi
from 98109
Murrieta, CA
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1008
mi
from 98109
Murrieta, CA
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
950
mi
from 98109
Tarzana, CA
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
950
mi
from 98109
Tarzana, CA
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1020
mi
from 98109
Denver, CO
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1020
mi
from 98109
Denver, CO
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2724
mi
from 98109
Aventura, FL
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2724
mi
from 98109
Aventura, FL
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2543
mi
from 98109
Bradenton, FL
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2543
mi
from 98109
Bradenton, FL
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2730
mi
from 98109
Coral Gables, FL
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2730
mi
from 98109
Coral Gables, FL
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2712
mi
from 98109
Pompano Beach, FL
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2712
mi
from 98109
Pompano Beach, FL
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1870
mi
from 98109
Bloomington, IN
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1870
mi
from 98109
Bloomington, IN
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1875
mi
from 98109
Greenwood, IN
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1875
mi
from 98109
Greenwood, IN
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2099
mi
from 98109
New Orleans, LA
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2099
mi
from 98109
New Orleans, LA
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2099
mi
from 98109
New Orleans, LA
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2099
mi
from 98109
New Orleans, LA
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2326
mi
from 98109
Greenbelt, MD
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2326
mi
from 98109
Greenbelt, MD
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2323
mi
from 98109
Towson, MD
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2323
mi
from 98109
Towson, MD
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2481
mi
from 98109
Chestnut Hill, MA
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2481
mi
from 98109
Chestnut Hill, MA
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
872
mi
from 98109
Las Vegas, NV
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
872
mi
from 98109
Las Vegas, NV
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2390
mi
from 98109
Edison, NJ
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2390
mi
from 98109
Edison, NJ
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1184
mi
from 98109
Albuquerque, NM
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1184
mi
from 98109
Albuquerque, NM
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2418
mi
from 98109
Garden City, NY
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2418
mi
from 98109
Garden City, NY
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2400
mi
from 98109
New York, NY
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2376
mi
from 98109
Newburgh, NY
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2376
mi
from 98109
Newburgh, NY
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2374
mi
from 98109
Poughkeepsie, NY
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2374
mi
from 98109
Poughkeepsie, NY
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2287
mi
from 98109
Concord, NC
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2287
mi
from 98109
Concord, NC
Click here to add this to my saved trials
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1967
mi
from 98109
Cincinnati, OH
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials